Altimmune Set to Showcase Innovations at Key Conferences

Author: Henry Turner Updated: 09-23-2025 07:50 AM

Altimmune's Upcoming Investor Conferences

GAITHERSBURG, Md. — Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company known for its innovative peptide-based therapeutics targeting liver and cardiometabolic diseases, has exciting news. Members of Altimmune's management team will be attending two notable investor conferences where they will engage in discussions, including one-on-one meetings with interested parties.

Details of the Conferences

Stifel 2025 Virtual Cardiometabolic Forum

The first conference, the Stifel 2025 Virtual Cardiometabolic Forum, is scheduled for a fireside chat on Tuesday, September 30, 2025 at 10:30 a.m. Eastern Time. This platform provides an excellent opportunity for investors to gain insights into Altimmune’s strategies and developments.

H.C. Wainwright Liver Disease Virtual Conference

Following closely is the H.C. Wainwright Liver Disease Virtual Conference on Tuesday, October 21, 2025 at 7:00 a.m. Eastern Time. This forum will further highlight Altimmune's commitment to addressing liver diseases and the therapeutic advancements they are making.

Accessing the Conference Sessions

For those unable to attend these events live, the sessions will be available via webcast. Interested parties can access these webcasts by visiting the Events section on the Altimmune website.

About Altimmune and Its Lead Product

Altimmune, Inc. is not just another biopharmaceutical player; it focuses on pioneering peptide-based therapeutics that cater to critical health issues such as liver and cardiometabolic diseases. Their leading product candidate, pemvidutide, works as a dual receptor agonist, making strides in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD), and obesity.

The Impact of Altimmune's Innovations

The work being done at Altimmune is crucial as it addresses significant health concerns in today's society. The company's innovative approach to therapeutic development sets it apart in a competitive industry, aiming to provide effective treatment solutions for patients facing serious health challenges.

Stay Connected with Altimmune

For ongoing updates, you can follow Altimmune on LinkedIn and X to stay informed about their journey, breakthroughs, and participation in various events such as these conferences.

Investor Contact Information

For more information, investors can reach out to Lee Roth from Burns McClellan at 646-382-3403 or contact him via email.

Frequently Asked Questions

What is the focus of Altimmune?

Altimmune specializes in developing peptide-based therapeutics for liver and cardiometabolic diseases.

When are the upcoming investor conferences?

The Stifel 2025 Virtual Cardiometabolic Forum is on September 30, 2025, and the H.C. Wainwright Liver Disease Virtual Conference is on October 21, 2025.

How can I access the conference sessions?

The sessions will be webcast and can be accessed through the Events section of Altimmune's website.

What is pemvidutide?

Pemvidutide is Altimmune's leading product candidate, functioning as a dual receptor agonist for treating various metabolic diseases.

Who can I contact for more information?

Investors can contact Lee Roth at Burns McClellan for details and inquiries regarding Altimmune.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.